Extracellular Targeting of Cell Signaling in Cancer

Strategies Directed at MET and RON Receptor Tyrosine Kinase Pathways

Nonfiction, Science & Nature, Science, Chemistry, Technical & Industrial
Cover of the book Extracellular Targeting of Cell Signaling in Cancer by , Wiley
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781119300212
Publisher: Wiley Publication: May 10, 2018
Imprint: Wiley Language: English
Author:
ISBN: 9781119300212
Publisher: Wiley
Publication: May 10, 2018
Imprint: Wiley
Language: English

International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progression

Extracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy. With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development.

A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progression

Extracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy. With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development.

A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment.

More books from Wiley

Cover of the book The Dark Side of Family Communication by
Cover of the book Performance-Based Certification by
Cover of the book Advances in Optical Imaging for Clinical Medicine by
Cover of the book How To Be Happy by
Cover of the book Engineered Carbohydrate-Based Materials for Biomedical Applications by
Cover of the book Mentoring as Transformative Practice: Supporting Student and Faculty Diversity by
Cover of the book Private Capital Markets by
Cover of the book Pediatric Incontinence by
Cover of the book Introduction to Coordination Chemistry by
Cover of the book Drying Phenomena by
Cover of the book Equine Nutrition and Feeding by
Cover of the book Fundamentals of Mechanical Vibrations by
Cover of the book Popular Protest in China by
Cover of the book Shipboard Power Systems Design and Verification Fundamentals by
Cover of the book Ecological Biochemistry by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy